Mesoblast (ASX:MSB) expanded its coverage for Ryoncil to 104 million US government- and private-insured lives, according to a Thursday filing with the Australian bourse.
Ryoncil is approved by the US Food and Drug Administration for mesenchymal stromal cell therapy.
It is the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months and older, a separate filing showed.
Mesoblast's shares were up nearly 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.